Plasma Biomarkers Screening by Multiplex ELISA Assay in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Plasma Biomarkers Screening by Multiplex ELISA Assay in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Immune checkpoint inhibitors (ICIs) are commonly used in patients with advanced non-small cell lung cancer (NSCLC). An unmet need remains for new biomarkers associated with ICIs. In this study, consecutive patients with advanced NSCLC treated with nivolumab or pembrolizumab were included. Plasma at...

Full description

Bibliographic Details
Main Authors: Adrien Costantini, Paul Takam Kamga, Catherine Julie, Alexandre Corjon, Coraline Dumenil, Jennifer Dumoulin, Julia Ouaknine, Violaine Giraud, Thierry Chinet, Martin Rottman, Jean-François Emile, Etienne Giroux Leprieur
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Cancers
Subjects:
non-small cell lung cancer
immune checkpoint inhibitor
biomarker
plasma
resistance
toxicity
Online Access:https://www.mdpi.com/2072-6694/13/1/97

Internet

https://www.mdpi.com/2072-6694/13/1/97

Similar Items